Prognostic scores in primary biliary cholangitis

References

• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67(1), 145–172 (2017).
   PubMed Web of Science ®Google Scholar
• Shaker M, Mansour N, John BV. Primary biliary cholangitis in males: pathogenesis, clinical presentation, and prognosis. Clin. Liver Dis. 26(4), 643–655 (2022).
   PubMed Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J. Hepatol. 56(5), 1181–1188 (2012).
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon R-E, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128(2), 297–303 (2005).
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J. Hepatol. 55(6), 1361–1367 (2011).
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Bruns T, Cheung A et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J. Hepatol. 60(6), 1249–1258 (2014).
   PubMed Web of Science ®Google Scholar
• ter Borg PCJ, Schalm SW, Hansen BE, van Buuren HR. Group for the DP study. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. results of a 10-yr cohort study involving 297 patients. J. Am. College Gastroenterol.|ACG 101(9), 2044–2050 (2006).
   PubMed Web of Science ®Google Scholar
• Lammers WJ, Hirschfield GM, Corpechot C et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 149(7), 1804–1812.e4 (2015).
   PubMed Web of Science ®Google Scholar
• Carbone M, Sharp SJ, Flack S et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 63(3), 930–950 (2016).
   PubMed Web of Science ®Google Scholar
• Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 69(1), 394–419 (2019).
   PubMed Web of Science ®Google Scholar
• Corpechot C, Abenavoli L, Rabahi N et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48(3), 871–877 (2008).
   PubMed Web of Science ®Google Scholar
• Kimura N, Takamura M, Takeda N et al. Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. Hepatol. Int. 15(2), 437–443 (2021).
   PubMed Web of Science ®Google Scholar
• Harms MH, Lammers WJ, Thorburn D et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. J. Am. Coll. Gastroenterol. 113(2), 254 (2018).
   PubMed Web of Science ®Google Scholar
• Murillo Perez CF, Harms MH, Lindor KD et al. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. J. Am. Coll. Gastroenterol. 115(7), 1066 (2020).
   PubMed Web of Science ®Google Scholar
• Gazda J, Drazilova S, Janicko M et al. Prognostic factors in primary biliary cholangitis: a retrospective study of joint Slovak and Croatian cohort of 249 patients. J. Pers. Med. 11(6), 495 (2021).
   PubMed Web of Science ®Google Scholar
• Joshita S, Umemura T, Ota M, Tanaka E. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. J. Hepatol. 61(6), 1443–1445 (2014).
   PubMed Web of Science ®Google Scholar
• Feng J, Xu J-M, Fu H-Y, Xie N, Bao W-M, Tang Y-M. Prognostic scores in primary biliary cholangitis patients with advanced disease. World J. Gastrointest. Surg. 15(8), 1774–1783 (2023).
   PubMed Web of Science ®Google Scholar
• Ito T, Ishigami M, Morooka H et al. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Sci Rep. 10(1), 17812 (2020).
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhong R, Wang Y et al. The albumin-bilirubin score as a predictor of liver-related mortality in primary biliary cholangitis with compensated cirrhosis. Dig. Dis. 41(6), 946–956 (2023).
   PubMed Web of Science ®Google Scholar
• Angulo P, Lindor KD, Therneau TM et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 19(2), 115–121 (1999).
   PubMedGoogle Scholar
• Kilmurry MR, Heathcote EJ, Cauch-Dudek K et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 23(5), 1148–1153 (1996).
   PubMed Web of Science ®Google Scholar
• Goet JC, Murillo Perez CF, Harms MH et al. A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis. Am. J. Gastroenterol. 116(7), 1514–1522 (2021).
   PubMed Web of Science ®Google Scholar
• de Veer RC, van Hooff MC, Corpechot C et al. Ursodeoxycholic acid treatment–induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis. J. Am. Coll. Gastroenterol.|ACG 118(7), 1196 (2023).
   PubMed Web of Science ®Google Scholar
• Alomari M, Covut F, Al Momani L et al. Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population. JGH Open 4(2), 132–139 (2020).
   PubMed Web of Science ®Google Scholar
• Yang F, Yang Y, Wang Q et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment. Pharmacol. Therap. 45(5), 733–743 (2017).
   PubMed Web of Science ®Google Scholar
• Carbone M, Nardi A, Flack S et al. Pre-treatment prediction of response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis: the UDCA Response Score. Lancet Gastroenterol. Hepatol. 3(9), 626–634 (2018).
   PubMed Web of Science ®Google Scholar
• Yagi M, Matsumoto K, Komori A et al. A validation study of the ursodeoxycholic acid response score in Japanese patients with primary biliary cholangitis. Liver Inter. 40(8), 1926–1933 (2020).
   PubMed Web of Science ®Google Scholar